CY1107096T1 - Μεθοδοι και φαρμακοτεχνικες μορφες ελεγχομενης απελευθερωσης παλιπεριδονης - Google Patents
Μεθοδοι και φαρμακοτεχνικες μορφες ελεγχομενης απελευθερωσης παλιπεριδονηςInfo
- Publication number
- CY1107096T1 CY1107096T1 CY20071101601T CY071101601T CY1107096T1 CY 1107096 T1 CY1107096 T1 CY 1107096T1 CY 20071101601 T CY20071101601 T CY 20071101601T CY 071101601 T CY071101601 T CY 071101601T CY 1107096 T1 CY1107096 T1 CY 1107096T1
- Authority
- CY
- Cyprus
- Prior art keywords
- paliperidone
- methods
- plasma concentration
- detection
- peak plasma
- Prior art date
Links
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 title abstract 6
- 229960001057 paliperidone Drugs 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 238000001514 detection method Methods 0.000 title 1
- 230000036470 plasma concentration Effects 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Προβλέπονται φαρμακοτεχνικές μορφές και μέθοδοι για παροχή ανοδικού κατ’ ουσία ρυθμού αποδέσμευσης παλιπεριδόνης. Οι φαρμακοτεχνικές μορφές παρατεταμένης αποδέσμευσης όταν χορηγούνται εφάπαξ ημερησίως, προσφέρουν θεραπευτικά αποτελεσματικές, μέσης σταθερής κατάστασης συγκεντρώσεις παλιπεριδόνης στοπλάσμα. Το σχήμα των εφάπαξ ημερησίων δόσεων έχει ως αποτέλεσμα να προκύπτει μια μόνο μέγιστη συγκέντρωση παλιπεριδόνης στο πλάσμα κατά την περίοδο του 24ώρου. Επιπλέον, η μέγιστη συγκέντρωση της παλιπεριδόνης στο πλάσμα, επέρχεται σε χρόνο μετά τη χορήγηση της δόσης και εμφανίζεται σε μικρότερο βαθμό σε σχέση με τη μέγιστη συγκέντρωση της παλιπεριδόνης στο πλάσμα που επέρχεται μετά τη χορήγηση παλιπεριδόνης σε φαρμακοτεχνική μορφή άμεσης αποδέσμευσης.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39959002P | 2002-07-29 | 2002-07-29 | |
US40600502P | 2002-08-26 | 2002-08-26 | |
EP03771910A EP1539115B1 (en) | 2002-07-29 | 2003-07-28 | Methods and dosage forms for controlled delivery of paliperidone |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1107096T1 true CY1107096T1 (el) | 2012-10-24 |
Family
ID=31191280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071101601T CY1107096T1 (el) | 2002-07-29 | 2007-12-18 | Μεθοδοι και φαρμακοτεχνικες μορφες ελεγχομενης απελευθερωσης παλιπεριδονης |
Country Status (29)
Country | Link |
---|---|
US (1) | US20040092534A1 (el) |
EP (1) | EP1539115B1 (el) |
JP (1) | JP4500679B2 (el) |
KR (1) | KR100699516B1 (el) |
CN (1) | CN1684670A (el) |
AR (1) | AR040721A1 (el) |
AT (1) | ATE373472T1 (el) |
AU (1) | AU2003256844A1 (el) |
BR (1) | BR0313139A (el) |
CA (1) | CA2494234C (el) |
CO (1) | CO5580742A2 (el) |
CY (1) | CY1107096T1 (el) |
DE (1) | DE60316454T2 (el) |
DK (1) | DK1539115T3 (el) |
ES (1) | ES2293039T3 (el) |
HK (1) | HK1072559A1 (el) |
HR (1) | HRP20050077B1 (el) |
IL (1) | IL166489A (el) |
MX (1) | MXPA05001191A (el) |
MY (1) | MY137049A (el) |
NO (1) | NO324821B1 (el) |
NZ (1) | NZ570198A (el) |
PE (1) | PE20040132A1 (el) |
PL (1) | PL210119B1 (el) |
PT (1) | PT1539115E (el) |
RU (1) | RU2321391C2 (el) |
TW (1) | TWI363637B (el) |
WO (1) | WO2004010981A1 (el) |
ZA (1) | ZA200501641B (el) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
DE602005008460D1 (de) * | 2004-08-04 | 2008-09-04 | Alza Corp | Zusammensetzung mit verzögerter arzneimittelfreisetzung mit einem aufsteigenden nullordnung-freigabe-muster; verfahren zur herstellung einer solchen zusammensetzung" |
WO2006085856A1 (en) * | 2005-02-04 | 2006-08-17 | Alza Corporation | Methods and dosage forms for reducing side effects of benzisozazole derivatives |
US20060189635A1 (en) * | 2005-02-04 | 2006-08-24 | Michelle Kramer | Enhanced efficacy benzisoxazole derivative dosage forms and methods |
EP1912622A2 (en) * | 2005-08-04 | 2008-04-23 | Alza Corporation | Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties |
US20070166381A1 (en) * | 2006-01-06 | 2007-07-19 | Iran Reyes | Osmotic dosage form with controlled release and fast release aspects |
SI3095447T1 (sl) | 2006-02-03 | 2022-02-28 | Opko Renal, Llc | Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3 |
US20070232624A1 (en) | 2006-04-03 | 2007-10-04 | Palumbo Joseph M | Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients |
PT2679228T (pt) | 2006-06-21 | 2018-04-16 | Opko Ireland Global Holdings Ltd | Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d |
US8524749B2 (en) * | 2007-02-09 | 2013-09-03 | Alza Corporation | Controlled release compositions of tizanidine |
PL2148684T3 (pl) | 2007-04-25 | 2013-06-28 | Cytochroma Inc | Sposób leczenia niedoboru i deficytu witaminy D |
PT2148661E (pt) | 2007-04-25 | 2013-03-06 | Proventiv Therapeutics Llc | Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso |
PT2079446E (pt) * | 2007-08-21 | 2011-12-23 | Teva Pharma | Formulação de libertação sustida de paliperidona |
KR101041203B1 (ko) | 2007-09-25 | 2011-06-13 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 이매티닙 조성물 |
EP2234617B1 (en) | 2007-12-19 | 2021-03-31 | Janssen Pharmaceutica NV | Dosing regimen associated with long acting injectable paliperidone esters |
US20090247553A1 (en) * | 2008-03-27 | 2009-10-01 | Actavis Group Ptc Ehf | Highly Pure Paliperidone or a Pharmaceutically Acceptable Salt Thereof Substantially Free of Keto Impurity |
WO2010009900A1 (en) * | 2008-07-25 | 2010-01-28 | Krka, D.D. Novo Mesto | Paliperidone composition comprising solid matrix particles |
EP2161019A1 (en) | 2008-09-05 | 2010-03-10 | KRKA, D.D., Novo Mesto | Prolonged release multiparticulate pharmaceutical composition comprising paliperidone |
WO2010044097A2 (en) | 2008-09-15 | 2010-04-22 | Intas Pharmaceuticals Limited | Novel dosage form of paliperidone and process for preparing the same |
BRPI0919465A2 (pt) * | 2008-09-30 | 2015-12-01 | Endo Pharmaceuticals Solutions | dispositivo implantável para a liberação de risperidona e métodos de uso do mesmo |
WO2011018246A2 (en) | 2009-08-13 | 2011-02-17 | Synthon B.V. | Controlled release paliperidone composition |
US20110052687A1 (en) * | 2009-08-26 | 2011-03-03 | Glenmark Generics Ltd | Extended release pharmaceutical composition of paliperidone |
EP2488162A2 (en) * | 2009-10-16 | 2012-08-22 | Ranbaxy Laboratories Limited | Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof |
EP2547206B1 (en) * | 2010-03-15 | 2016-05-11 | Inventia Healthcare Private Limited | Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic |
PT2552484T (pt) | 2010-03-29 | 2020-04-03 | Opko Ireland Global Holdings Ltd | Métodos e composições para redução dos níveis de parafróides |
ES2602503T3 (es) | 2010-04-22 | 2017-02-21 | Intra-Cellular Therapies, Inc. | Compuestos orgánicos |
US20120201886A1 (en) | 2010-07-30 | 2012-08-09 | Micro Labs Limited | Coated Extended Release Pharmaceutical Compositions Containing Paliperidone |
CN102058517A (zh) * | 2010-12-31 | 2011-05-18 | 泰州万全医药科技有限公司 | 一种帕潘立酮缓释剂及其制备方法 |
US20130034605A1 (en) | 2011-08-01 | 2013-02-07 | Micro Labs Limited | Extended release pharmaceutical compositions containing paliperidone |
CN102274164B (zh) * | 2011-08-22 | 2014-07-02 | 长春健欣生物医药科技开发有限公司 | 帕潘立酮及帕潘立酮衍生物的注射用缓释凝胶剂 |
IN2014DN08562A (el) | 2012-04-14 | 2015-05-22 | Intra Cellular Therapies Inc | |
WO2014102741A2 (en) * | 2012-12-28 | 2014-07-03 | University Of The Witwatersrand, Johannesburg | Pharmaceutical dosage form |
KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 d 방출 제형 |
PT2968320T (pt) | 2013-03-15 | 2021-01-28 | Intra Cellular Therapies Inc | Compostos orgânicos |
CN103271889B (zh) * | 2013-05-23 | 2015-10-28 | 沈阳药科大学 | 帕利哌酮新型递增释放渗透泵制剂及其制备方法 |
CN103385857A (zh) * | 2013-06-29 | 2013-11-13 | 北京万全德众医药生物技术有限公司 | 帕利哌酮的药物组合物 |
WO2015001488A1 (en) | 2013-07-01 | 2015-01-08 | Ranbaxy Laboratories Limited | Extended-release tablets of paliperidone and processes of preparation thereof |
PL3076967T3 (pl) | 2013-12-03 | 2021-12-20 | Intra-Cellular Therapies, Inc. | Metody leczenia objawów rezydualnych schizofrenii |
US9745300B2 (en) | 2014-04-04 | 2017-08-29 | Intra-Cellular Therapies, Inc. | Organic compounds |
BR112016023162B1 (pt) | 2014-04-04 | 2022-11-29 | Intra-Cellular Therapies, Inc | Compostos orgânicos gama-carbolinas, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento ou na profilaxia de transtornos de sistema nervoso central |
US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
US20160000654A1 (en) * | 2014-07-07 | 2016-01-07 | Cadila Healthcare Limited | Method for determining formulation orientation of asymmetric multi-layered osmotic tablets |
EP3193925A2 (en) | 2014-08-07 | 2017-07-26 | OPKO Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin d |
CN104257622B (zh) * | 2014-10-01 | 2020-02-07 | 浙江华海药业股份有限公司 | 一种帕利哌酮控释片及其制备方法 |
US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
GR1008842B (el) | 2015-08-06 | 2016-09-05 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου |
CN105147629B (zh) * | 2015-09-24 | 2017-08-25 | 吉林大学 | 一种异丁利酮片剂及制备方法 |
MX2018009158A (es) | 2016-01-26 | 2018-11-19 | Intra Cellular Therapies Inc | Compuestos organicos. |
PL3407889T3 (pl) | 2016-03-25 | 2021-11-22 | Intra-Cellular Therapies, Inc. | Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego |
MX2018011820A (es) | 2016-03-28 | 2019-01-24 | Opko Ireland Global Holdings Ltd | Metodos de tratamiento con vitamina d. |
WO2017172795A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
US20190105277A1 (en) | 2016-04-05 | 2019-04-11 | Pharmathen S.A. | Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof |
EP3525763A4 (en) | 2016-10-12 | 2020-06-17 | Intra-Cellular Therapies, Inc. | AMORPHE FIXED DISPERSIONS |
US20190321367A1 (en) * | 2016-11-23 | 2019-10-24 | Children's Hospital Medical Center | Paliperidone for treatment of drug refractory irritability and autism spectrum disorder |
CN106727392A (zh) * | 2016-12-15 | 2017-05-31 | 上海奕利制药有限公司 | 一种帕利哌酮缓释片剂及其制备方法 |
JP6987868B2 (ja) | 2016-12-29 | 2022-01-05 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
US10961245B2 (en) | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
CN116327770A (zh) | 2017-03-24 | 2023-06-27 | 细胞内治疗公司 | 新组合物和方法 |
US11427587B2 (en) | 2017-07-26 | 2022-08-30 | Intra-Cellular Therapies, Inc. | Organic compounds |
CN111093665A (zh) | 2017-07-26 | 2020-05-01 | 细胞内治疗公司 | 有机化合物 |
CA3094949A1 (en) | 2018-03-23 | 2019-09-26 | Intra-Cellular Therapies, Inc. | Deuterated heterocycle fused gamma-carbolines |
BR112021003655A2 (pt) | 2018-08-31 | 2021-05-18 | Intra-Cellular Therapies, Inc. | métodos novos |
EP3843739A4 (en) | 2018-08-31 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NEW METHODS |
KR102285510B1 (ko) | 2019-10-29 | 2021-08-04 | 강동국 | 양액 농도조절용 캡슐 및 그 용도 |
CN113616610B (zh) * | 2021-07-30 | 2023-05-12 | 石药集团欧意药业有限公司 | 一种帕利哌酮缓释片及其制备方法 |
US20230364009A1 (en) * | 2022-05-12 | 2023-11-16 | Celanese Eva Performance Polymers Llc | Implantable Medical Device for the Delivery of an Antipsychotic |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4656092A (en) * | 1985-10-15 | 1987-04-07 | R. P. Scherer Corporation | Target shooting capsules |
GB8613688D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
IL92966A (en) * | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
US5156850A (en) * | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
ATE398448T1 (de) * | 1993-09-28 | 2008-07-15 | Scherer Gmbh R P | Herstellung von weichgelatinekapseln |
TW487572B (en) * | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
CA2263558A1 (en) * | 1996-08-16 | 1998-02-19 | Alza Corporation | Dosage form for providing ascending dose of drug |
US6919373B1 (en) * | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
DK1083879T3 (da) * | 1998-06-03 | 2005-01-31 | Alza Corp | Indretninger til at tilvejebringe forlænget medikamentterapi |
US6706282B1 (en) * | 1998-11-02 | 2004-03-16 | Evangeline Cruz | Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones |
KR20070040421A (ko) * | 1998-11-02 | 2007-04-16 | 알자 코포레이션 | 항우울제의 제어된 전달 |
DK1140012T3 (da) * | 1998-12-17 | 2004-07-12 | Alza Corp | Omdannelse af væskefyldte gelatinekapsler til systemer til kontrolleret frigivelsessystemer ved flere coatinger |
KR100660594B1 (ko) * | 1999-03-31 | 2006-12-22 | 얀센 파마슈티카 엔.브이. | 방출 조절형 제제중의 프리젤라틴화 전분 |
US6599532B2 (en) * | 2000-01-13 | 2003-07-29 | Osmotica Corp. | Osmotic device containing alprazolam and an antipsychotic agent |
US6491949B2 (en) * | 2000-01-14 | 2002-12-10 | Osmotica Corp. | Osmotic device within an osmotic device |
US6375981B1 (en) * | 2000-06-01 | 2002-04-23 | A. E. Staley Manufacturing Co. | Modified starch as a replacement for gelatin in soft gel films and capsules |
US6530962B1 (en) * | 2001-08-31 | 2003-03-11 | R.P. Scherer Technologies, Inc. | Emulsion of water soluble dyes in a lipophilic carrier |
-
2003
- 2003-07-28 MX MXPA05001191A patent/MXPA05001191A/es active IP Right Grant
- 2003-07-28 US US10/629,211 patent/US20040092534A1/en not_active Abandoned
- 2003-07-28 ES ES03771910T patent/ES2293039T3/es not_active Expired - Lifetime
- 2003-07-28 NZ NZ570198A patent/NZ570198A/en not_active IP Right Cessation
- 2003-07-28 AT AT03771910T patent/ATE373472T1/de active
- 2003-07-28 DE DE60316454T patent/DE60316454T2/de not_active Expired - Lifetime
- 2003-07-28 PL PL376258A patent/PL210119B1/pl unknown
- 2003-07-28 DK DK03771910T patent/DK1539115T3/da active
- 2003-07-28 AU AU2003256844A patent/AU2003256844A1/en not_active Abandoned
- 2003-07-28 KR KR1020057001460A patent/KR100699516B1/ko active IP Right Review Request
- 2003-07-28 PT PT03771910T patent/PT1539115E/pt unknown
- 2003-07-28 CN CNA03822948XA patent/CN1684670A/zh active Pending
- 2003-07-28 CA CA002494234A patent/CA2494234C/en not_active Expired - Lifetime
- 2003-07-28 BR BR0313139-4A patent/BR0313139A/pt not_active Application Discontinuation
- 2003-07-28 WO PCT/US2003/023433 patent/WO2004010981A1/en active IP Right Grant
- 2003-07-28 EP EP03771910A patent/EP1539115B1/en not_active Revoked
- 2003-07-28 RU RU2005102105/15A patent/RU2321391C2/ru not_active Application Discontinuation
- 2003-07-28 JP JP2004524886A patent/JP4500679B2/ja not_active Expired - Lifetime
- 2003-07-29 AR AR20030102717A patent/AR040721A1/es unknown
- 2003-07-29 MY MYPI20032846A patent/MY137049A/en unknown
- 2003-07-29 TW TW092120703A patent/TWI363637B/zh not_active IP Right Cessation
- 2003-07-30 PE PE2003000749A patent/PE20040132A1/es not_active Application Discontinuation
-
2005
- 2005-01-25 IL IL166489A patent/IL166489A/en active IP Right Grant
- 2005-01-25 HR HRP20050077AA patent/HRP20050077B1/hr not_active IP Right Cessation
- 2005-02-22 NO NO20050956A patent/NO324821B1/no not_active IP Right Cessation
- 2005-02-24 ZA ZA2005/01641A patent/ZA200501641B/en unknown
- 2005-02-28 CO CO05018509A patent/CO5580742A2/es not_active Application Discontinuation
- 2005-06-28 HK HK05105362A patent/HK1072559A1/xx not_active IP Right Cessation
-
2007
- 2007-12-18 CY CY20071101601T patent/CY1107096T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107096T1 (el) | Μεθοδοι και φαρμακοτεχνικες μορφες ελεγχομενης απελευθερωσης παλιπεριδονης | |
BR0309620A (pt) | Métodos e formas de dosagem para liberação controlada de oxicodona | |
DK1708686T3 (da) | Generelt lineær effervescent oral fentanyldoseringsform og fremgangsmåder til indgivelse | |
AR062320A1 (es) | Formulaciones de flibanserina y metodo para fabricarlas | |
NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
NO20080827L (no) | Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon | |
ATE431738T1 (de) | Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist | |
ES2153338T1 (es) | Dosificacion mejorada de dosis multiples de medicamentos. | |
MX2009013574A (es) | Formas de dosificacion solidas o semisolidas de liberacion modificada. | |
TW200505498A (en) | Sugar-free oral transmucosal solid dosage forms and uses thereof | |
EP1708685A4 (en) | GALENIC FORMS OF EFFERVESCENT ORAL OPIATES AND METHODS OF ADMINISTERING OPIATES | |
NO20051854L (no) | Vedvarende frigivelse opioidformuleringer og fremgangsmater for anvendelse. | |
CY1106137T1 (el) | Φαρμακευτικη συνθεση πepιλαμβανουσα λουμιρακοξιμπη | |
CO5640120A2 (es) | Formulacion y metodods para el tratamiento de trombocitemia | |
TR200103613T2 (tr) | Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler. | |
DE60313359D1 (de) | Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate | |
NO20073403L (no) | Anvendelse av atazanavir til forbedring av farmakokinetikken til legemidler metabolisert av UGT1A1 | |
EE04606B1 (et) | H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks | |
ATE541562T1 (de) | Ibuprofen-suspension | |
EA200401227A1 (ru) | Система доставки лекарства с контролируемым высвобождением, включающая правастатин | |
AP2003002763A0 (en) | Controlled release formulations for oral administration | |
DE60030283D1 (de) | Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen | |
WO2005010022A3 (en) | Agonist polypeptide of receptor for zot and zonulin | |
WO2003020214A3 (en) | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | |
CO5550418A2 (es) | Formulaciones antihistaminicas para formas de dosificacion de capsula blanda |